TOKYO, Mar 19 (Pulse News Wire) – Kissei Pharmaceutical CO.,LTD. (4547.T) announced today the launch of its new endometriosis treatment, Yselty® Tablets 100mg (generic name: Linzagolix Colamine).
The drug, an oral GnRH antagonist, inhibits gonadotropin secretion by antagonizing GnRH receptors in the pituitary gland, thereby reducing estrogen production in the ovaries and improving symptoms associated with uterine fibroids. Kissei reports that more than half of women experience uterine fibroids at some point in their lives, particularly affecting those aged 30 to 40. Symptoms such as heavy menstrual bleeding and chronic pain significantly impact quality of life and social activities. To address this issue, Kissei launched the disease awareness site “be loving” to enhance medical accessibility for women suffering from various gynecological conditions.
Additionally, overseas partners have advanced development efforts. In Europe, Ceramex (UK) began selling Yselty in September 2024, followed by approval for additional indications from the European Medicines Agency (EMA) in November 2024. Taiwanese partner Simosa Biopharma is preparing for release, while Korean and Canadian affiliates continue development. Regarding future outlook, there are no changes to Kissei's consolidated performance forecast for the fiscal year ending March 2026.
🟢 Confidence: High AI-translated content.